News | July 11, 2022
India’s first homegrown mRNA COVID-19 vaccine likely to have low market penetration, says GlobalData
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
Corbevax is administered through an intramuscular route with two doses scheduled 28 days apart and is stored between 2 degrees celsius to 8 degrees celsius
Subscribe To Our Newsletter & Stay Updated
